<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04086043</url>
  </required_header>
  <id_info>
    <org_study_id>EDNT2DM-2019</org_study_id>
    <nct_id>NCT04086043</nct_id>
  </id_info>
  <brief_title>The MILESTONE Study</brief_title>
  <official_title>MultI-eLectrode EndovaScular denervaTiOn in patieNts With Type 2 Diabetes mEllitus (MILESTONE) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongda Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongda Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sympathetic overactivity induces insulin resistance and type 2 diabetes mellitus (T2DM), so
      it is assumed that denervation might reduce sympathetic overactivity and improve glucose
      metabolism and insulin sensitivity. The purpose of this study is to evaluate the effects of
      multi-electrode catheter-based endovascular denervation on glucose metabolism and insulin
      sensitivity in patients with T2DM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sympathetic overactivity induces insulin resistance and type 2 diabetes mellitus (T2DM), so
      it is assumed that denervation might improve glucose metabolism and insulin sensitivity. Some
      clinical studies have shown that glucose metabolism is improved in patients with resistant
      hypertension both 1 and 3 months after denervation, and fasting glucose, insulin and
      C-peptide decreased significantly as did insulin resistance assessed by HOMA-IR. But in some
      clinical studies, denervation did not lead to a significant improvement of insulin
      sensitivity ≤12 months after treatment, and no effect in systemic sympathetic activity was
      observed after denervation. Therefore, the efficacy of denervation on glucose metabolism is
      still in controversy. The investigators wish to investigate the effect of multi-electrode
      catheter-based endovascular denervation on glucose metabolism and insulin sensitivity in
      patients with T2DM.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 10, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 9, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Oral Glucose Tolerance Test from baseline to 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>To investigate the influence of endovascular denervation on Oral Glucose Tolerance Test (OGTT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in glycosylated hemoglobin from baseline to 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>To investigate the influence of endovascular denervation on glycosylated hemoglobin (HbA1c).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Oral Glucose Tolerance Test up to 2 years</measure>
    <time_frame>3, 12 and 24 months</time_frame>
    <description>To investigate the influence of endovascular denervation on Oral Glucose Tolerance Test (OGTT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glycosylated hemoglobin up to 2 years</measure>
    <time_frame>3, 12 and 24 months</time_frame>
    <description>To investigate the influence of endovascular denervation on glycosylated hemoglobin (HbA1c).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in insulin up to 2 years</measure>
    <time_frame>3, 6, 12 and 24 months</time_frame>
    <description>To investigate the influence of endovascular denervation on insulin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in catecholamine up to 2 years</measure>
    <time_frame>3, 6, 12 and 24 months</time_frame>
    <description>To investigate the influence of endovascular denervation on catecholamine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glucagon up to 2 years</measure>
    <time_frame>3, 6, 12 and 24 months</time_frame>
    <description>To investigate the influence of endovascular denervation on glucagon.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood pressure up to 2 years</measure>
    <time_frame>3, 6, 12 and 24 months</time_frame>
    <description>To investigate the influence of endovascular denervation on blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in creatinine up to 2 years</measure>
    <time_frame>3, 6, 12 and 24 months</time_frame>
    <description>To investigate the influence of endovascular denervation on creatinine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood urea nitrogen (BUN) up to 2 years</measure>
    <time_frame>3, 6, 12 and 24 months</time_frame>
    <description>To investigate the influence of endovascular denervation on BUN.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Endovascular Denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endovascular Denervation</intervention_name>
    <description>multi-electrode catheter-based endovascular denervation</description>
    <arm_group_label>Endovascular Denervation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 18 years and ≤ 70 years old

          -  Able and willing to provide informed consent

          -  Patients with established type II diabetes mellitus (HbA1C&gt;7.5%, diet or oral
             hypoglycaemic agents)

          -  Clinical stable as demonstrated by no change in background anti-diabetic medication in
             the last 30 days.

          -  Anticipated that patients are able to maintain a stable dose of medication for the
             duration of the study

        Exclusion Criteria:

          -  Arterial anatomy ineligible for endovascular denervation

          -  History of prior renal artery intervention including balloon angioplasty, stenting or
             previous renal denervation

          -  Type 1 diabetes mellitus

          -  Pregnant, nursing or planning to be pregnant

          -  Orthostatic hypotension

          -  eGFR &lt;30 ml/min (MDRD formula)

          -  Patients that have allergy to contrast agent

          -  Myocardial infarction, unstable angina pectoris, coronary bypass or percutaneous
             angioplasty within 3 months before inclusion

          -  Cerebrovascular accidents and alimentary tract hemorrhage within 3 months before
             inclusion

          -  Any medical condition which, in the investigators opinion, may adversely affect the
             participants safety in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gao-Jun Teng,, MD</last_name>
    <phone>+86 25 83272121</phone>
    <email>gjteng@seu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tao Pan, PhD</last_name>
    <phone>+86-15850651223</phone>
    <email>15850651223@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongda Hospital, Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gao-Jun Teng, MD</last_name>
      <phone>+86 25 83272121</phone>
      <email>gjteng@seu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Tao Pan, PhD</last_name>
      <phone>+86-15850651223</phone>
      <email>15850651223@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gao-Jun Teng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 5, 2019</study_first_submitted>
  <study_first_submitted_qc>September 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhongda Hospital</investigator_affiliation>
    <investigator_full_name>Gao-jun Teng</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

